Sign in
HARP Stock Price, Chart, Stats & News
Harpoon Therapeutics, Inc.
Save
865.08M
Market cap
–
Current P/E
–
Forward P/E
HARP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.30% |
Operating margin | -214.08% |
Pretax margin | -212.22% |
Net margin | -210.36% |
Effective tax rate | 0.88% |
ROA | -91.06% |
ROE | -211.56% |
D/E | 2.96x |
Interest coverage ratio | – |
HARP valuation
P/E | – |
P/S | 27.11x |
P/B | 14.14x |
P/CF | -0.86x |
P/FCF | -9.66x |
P/OCF | -0.86x |
PEG | -0.01x |
EV multiple | -13.65x |
About
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline.
Similar securities
Based on sector and market capitalization
Report issue